Profile change history

What changed for TB-500?

A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed TB-500 identity.

11Total events
7Record additions
4Version changes
3Cited source years

Before and after

Preserved version changes

Record updated

ClinicalTrials.gov record NCT07487363

ClinicalTrials.gov posted a newer version of NCT07487363, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.

PeptideScanner change date
November 15, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials

Summary

Before
PeptideScanner retained ClinicalTrials.gov record NCT07487363 at 2026-07-30T16:22:22.342Z. Its registry update date was 2026-03-23, and PeptideScanner's reviewed identity mapping was tb-500.
After
PeptideScanner retained ClinicalTrials.gov record NCT07487363 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tb-500.

Cited source date

Before
2026-03-23
After
2026-11-12

Source observed date

Before
2026-07-30
After
2026-11-15

Cited source records

Before
ctg-observation-nct07487363-2026-03-23-eb4b60623fcf
After
ctg-observation-nct07487363-2026-03-23-eb4b60623fcf-r2

Headline citations

Before
ctg-observation-nct07487363-2026-03-23-eb4b60623fcf
After
ctg-observation-nct07487363-2026-03-23-eb4b60623fcf-r2

Summary citations

Before
ctg-observation-nct07487363-2026-03-23-eb4b60623fcf
After
ctg-observation-nct07487363-2026-03-23-eb4b60623fcf-r2

Attributable context

Before
1. PeptideScanner retained ClinicalTrials.gov record NCT07487363 at 2026-07-30T16:22:22.342Z. Its registry update date was 2026-03-23, and PeptideScanner's reviewed identity mapping was tb-500. [sources: ctg-observation-nct07487363-2026-03-23-eb4b60623fcf] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07487363-2026-03-23-eb4b60623fcf]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT07487363 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tb-500. [sources: ctg-observation-nct07487363-2026-03-23-eb4b60623fcf-r2] 2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07487363-2026-03-23-eb4b60623fcf-r2]

Source snapshot commitment

Before
d7340d8da0bedde68aaaca06505e04d72aa1c49971d4f34e584ac543e56c8ed6
After
dee9c9d5083b9463d9b874710e1cfe524293c68c31954d4c2e5d9f1276bf9827
Profile status changed

TB-500 profile

We added a plain-language reader guide with cited answers, re-checked FDA’s TB-500 briefing, added a registered trial, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists TB-500 acetate. FDA has not issued a final 503A rule.

PeptideScanner change date
November 14, 2026
Evidence lane
Profile

Status

Before
FDA compounding assessment in the cited records
After
Not an FDA-approved drug

Profile summary

Before
A thymosin beta-4 fragment represented in FDA identity and pharmacy-compounding review records.
After
A synthetic seven-amino-acid fragment of thymosin beta-4 that is not FDA-approved. FDA’s 2026 review found no studies of TB-500 in people.

Evidence note

Before
FDA's July 2026 briefing evaluates TB-500-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.
After
FDA staff recommended in May 2026 against adding TB-500 to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists TB-500 acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make TB-500 an FDA-approved drug.

Cited source records

Before
fda-tb-500-identity, fda-tb-500-briefing, fda-pcac-peptide-meeting-2026
After
fda-tb-500-identity, fda-tb-500-briefing, fda-pcac-peptide-meeting-2026, fda-bulk-peptide-risks, ctg-observation-nct07487363-2026-03-23-eb4b60623fcf, federal-register-2026-07361-0aed508462b2, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026

Named organizations

Before
U.S. Food and Drug Administration [sources: fda-tb-500-identity, fda-tb-500-briefing, fda-pcac-peptide-meeting-2026]
After
U.S. Food and Drug Administration [sources: fda-tb-500-identity, fda-tb-500-briefing, fda-pcac-peptide-meeting-2026]; U.S. Department of Health and Human Services [sources: hhs-503a-peptide-enforcement-discretion-notice-2026]

Claim citations

Before
name: fda-tb-500-identity, fda-tb-500-briefing; aliases: fda-tb-500-identity, fda-tb-500-briefing; category: fda-tb-500-briefing; status: fda-tb-500-briefing; summary: fda-tb-500-identity, fda-tb-500-briefing; evidenceNote: fda-tb-500-briefing
After
name: fda-tb-500-identity, fda-tb-500-briefing; aliases: fda-tb-500-identity, fda-tb-500-briefing; category: fda-tb-500-briefing; status: fda-tb-500-briefing; summary: fda-tb-500-briefing; evidenceNote: fda-tb-500-briefing, fda-pcac-peptide-meeting-2026, hhs-503a-peptide-enforcement-discretion-notice-2026, hhs-503a-peptide-enforcement-discretion-policy-2026
Correction

TB-500 profile

We narrowed the status wording to what the dated FDA briefing establishes. A briefing prepared for an advisory process does not establish the current absence of a later final decision. Related substance identities remain distinct.

PeptideScanner change date
September 15, 2026
Evidence lane
Profile

Status

Before
FDA compounding safety review; final determination pending
After
FDA compounding assessment in the cited records

Evidence note

Before
FDA's identity record maps TB-500 to a thymosin beta-4 fragment, while FDA's July 2026 briefing addresses its pharmacy-compounding review. Committee recommendations are nonbinding, and FDA's final determination remains pending.
After
FDA's July 2026 briefing evaluates TB-500-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.

Claim citations

Before
name: fda-tb-500-identity, fda-tb-500-briefing; aliases: fda-tb-500-identity, fda-tb-500-briefing; category: fda-tb-500-briefing; status: fda-tb-500-briefing, fda-pcac-peptide-meeting-2026; summary: fda-tb-500-identity, fda-tb-500-briefing; evidenceNote: fda-tb-500-identity, fda-tb-500-briefing, fda-pcac-peptide-meeting-2026
After
name: fda-tb-500-identity, fda-tb-500-briefing; aliases: fda-tb-500-identity, fda-tb-500-briefing; category: fda-tb-500-briefing; status: fda-tb-500-briefing; summary: fda-tb-500-identity, fda-tb-500-briefing; evidenceNote: fda-tb-500-briefing
Profile status changed

TB-500 profile

We added FDA's July 2026 pharmacy-compounding review and changed the display status from identity-only to a pending safety review without implying a final FDA determination.

PeptideScanner change date
July 29, 2026
Evidence lane
Profile

Status

Before
FDA identity record only; approval status not established
After
FDA compounding safety review; final determination pending

Status classification

Before
identity-only
After
safety-review

Topic

Before
Identity records
After
Safety records

Profile summary

Before
A research-peptide name that FDA's substance registry maps to a thymosin beta-4 fragment.
After
A thymosin beta-4 fragment represented in FDA identity and pharmacy-compounding review records.

Evidence note

Before
FDA's substance registry identifies TB-500 as an N-terminal acetylated 17-23 fragment of thymosin beta-4 and explicitly states that a UNII record does not imply regulatory review or approval.
After
FDA's identity record maps TB-500 to a thymosin beta-4 fragment, while FDA's July 2026 briefing addresses its pharmacy-compounding review. Committee recommendations are nonbinding, and FDA's final determination remains pending.

Cited source records

Before
fda-tb-500-identity
After
fda-tb-500-identity, fda-tb-500-briefing, fda-pcac-peptide-meeting-2026

Named organizations

Before
U.S. Food and Drug Administration [sources: fda-tb-500-identity]
After
U.S. Food and Drug Administration [sources: fda-tb-500-identity, fda-tb-500-briefing, fda-pcac-peptide-meeting-2026]

Claim citations

Before
name: fda-tb-500-identity; aliases: fda-tb-500-identity; category: fda-tb-500-identity; status: fda-tb-500-identity; summary: fda-tb-500-identity; evidenceNote: fda-tb-500-identity
After
name: fda-tb-500-identity, fda-tb-500-briefing; aliases: fda-tb-500-identity, fda-tb-500-briefing; category: fda-tb-500-briefing; status: fda-tb-500-briefing, fda-pcac-peptide-meeting-2026; summary: fda-tb-500-identity, fda-tb-500-briefing; evidenceNote: fda-tb-500-identity, fda-tb-500-briefing, fda-pcac-peptide-meeting-2026

Collection chronology

Evidence added to PeptideScanner

Browse all 7 connected records →

Showing the latest 7 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: August 21, 2026.

Record added

Federal Register notice 2026-07361

The Federal Register published notice 2026-07361, attributed to FDA and its parent HHS department, on 2026-04-16. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List,” and PeptideScanner's exact reviewed identity mapping connects the document to BPC-157, Emideltide, Epitalon, KPV, MOTS-c, Semax and TB-500.

PeptideScanner change date
August 21, 2026
Cited source date
April 16, 2026
Evidence lane
Regulatory
Record added

ClinicalTrials.gov record NCT07487363

PeptideScanner retained ClinicalTrials.gov record NCT07487363 at 2026-07-30T16:22:22.342Z. Its registry update date was 2026-03-23, and PeptideScanner's reviewed identity mapping was tb-500.

PeptideScanner change date
August 14, 2026
Cited source date
March 23, 2026
Evidence lane
Clinical trials
Record added

PubMed record PMID 22962027

PeptideScanner retained PubMed bibliographic metadata for PMID 22962027 at 2026-07-30T16:30:49.822Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2012-09-11. PeptideScanner associated this retained record with the identity slug tb-500. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
January 28, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 23084823

PeptideScanner retained PubMed bibliographic metadata for PMID 23084823 at 2026-07-30T16:30:49.836Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2012-10-23. PeptideScanner associated this retained record with the identity slug tb-500. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
January 28, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 28887173

PeptideScanner retained PubMed bibliographic metadata for PMID 28887173 at 2026-07-30T21:13:36.164Z. PubMed recorded a metadata revision date of 2018-02-08 and an Entrez history date of 2017-09-10. PeptideScanner associated this retained record with the identity slug tb-500. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
February 8, 2018
Evidence lane
Literature metadata
Record added

PubMed record PMID 38382158

PeptideScanner retained PubMed bibliographic metadata for PMID 38382158 at 2026-07-30T18:48:13.580Z. PubMed recorded a metadata revision date of 2024-03-11 and an Entrez history date of 2024-02-21. PeptideScanner associated this retained record with the identity slug tb-500. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
March 11, 2024
Evidence lane
Literature metadata
Record added

FDA committee met on seven peptide-related groups of bulk drug substances

FDA convened its Pharmacy Compounding Advisory Committee on July 23-24, 2026, to discuss free-base and acetate bulk drug substances across seven peptide-related groups.

PeptideScanner change date
July 29, 2026
Cited source date
July 24, 2026
Evidence lane
Regulatory